# MTLS earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/MTLS) · [Earnings tab](https://www.lopjlb.com/stock/MTLS?tab=earnings)

Updated: 2026-08-28T06:49:34

Quarters analyzed: 8

## Cross-quarter narrative

From Q3 2024 through Q2 2026 Materialise’s earnings calls trace a shift from rapid capacity expansion and early‑stage partnership rollout toward disciplined cash generation and selective divestments. Medical revenue, already the dominant segment, moved from 44% of sales and +14% YoY growth in Q3 2024 to sustained double‑digit growth (≈10‑12% YoY) by Q2 2026, underpinning a higher medical EBITDA margin despite FX headwinds. Software transitioned from a long‑tail perpetual‑license model to recurring subscriptions, with recurring EBITDA rising sharply in 2026, yet the segment still faced cautious industrial spending and extended sales cycles. Manufacturing, pressured by a challenging European industrial environment and the ACTech plant start‑up, posted negative adjusted EBITDA in 2025 but turned positive by Q1 2026 as aerospace/defense demand recovered and cost discipline tightened. Macro‑economic uncertainty, weaker European automotive demand, and foreign‑exchange volatility remained recurring concerns. Strategic actions included completing the US medical plant, launching the CO‑AM suite, and divesting RapidFit and Eyewear to sharpen focus on core medical and software businesses. Overall, the narrative reflects improving profitability, continued macro risk, and a clearer focus on high‑margin medical and software offerings.

## Latest CallCard · Q2

Materialise Q2 2026: Revenue up 8% to EUR 70.1M, Medical +12%, Software -3%, Manufacturing +7%; adjusted EBIT margin expands to 5.5%; net cash rises to EUR 74.2M; full-year revenue guidance maintained EUR 273-283M, adjusted EBIT guidance raised to EUR 12-14M; RapidFit and Eyewear divestments complet

**Guidance:** raised — Revenue guidance maintained at EUR 273-283M; adjusted EBIT guidance raised to EUR 12-14M from EUR 10-12M, reflecting stronger execution and cost discipline.

**Tone:** mgmt 0.7 · Q&A pressure 0.4 · divergence 0.3

Management highlighted broad-based growth, margin expansion, strategic portfolio sharpening, and raised EBIT guidance while reaffirming revenue guidance, expressing confidence in structural growth and execution.

### Demand visibility

Medical structural growth ~10% sustainable; Software facing cautious industrial spending and extended sales cycles; Manufacturing aerospace/defense strong, prototyping weak.

Medical Devices grew 19% driven by partner and direct channels; Medical Software declined 4% due to US academic research grant reductions and orthopedic reimbursement changes. Software segment sees 86% recurring revenue but cautious customer spending. Manufacturing Aerospace +40% revenue growth, defense momentum via Strike IP consortium, prototyping demand remains weak.

### Margins / costs

Gross margin stable at 56.8%; adjusted EBIT margin expanded to 5.5% driven by revenue growth, cost discipline, and portfolio optimization.

Adjusted EBITDA margin 13.7% in Q2; half-year adjusted EBITDA margin 12.9%. Operating expenses up 3.9% in Q2 (R&D +11%), half-year up only 2%. Gross profit EUR 39.8M. Cost actions and portfolio optimization (divestments) improving Manufacturing EBITDA toward breakeven.

### Capital allocation

Strong cash generation, net cash up to EUR 74.2M; share buyback EUR 5.2M in H1 (1.1M ADS, 1.8% share base); debt reduced; divestments completed to focus capital on core growth.

Cash reserve EUR 133.7M, gross debt EUR 59.5M. Operating cash flow Q2 >EUR 8M, half-year EUR 50M. Free cash flow H1 EUR 11.4M (almost double prior year). CapEx H1 EUR 3.4M (recurring EUR 2.7M). RapidFit and Eyewear divestments closed; 20% minority stake retained in Eyewear.

### Milestones

- **CO-AM Pro launch** [delivered]: Officially released May 15, 2026, one month ahead of schedule; cloud-based solution integrated with Magics for AM data management and build preparation.
- **CO-AM Bricks offering** [delivered]: Formally released automation platform to reduce manual work and embed AM know-how; early customer onboarding shows encouraging validation.
- **CO-AM NPI and Enterprise early adopter programs** [new]: Started early adopter programs for CO-AM NPI and CO-AM Enterprise; positioned as major growth drivers for scaling additive manufacturing in aerospace/defense.
- **RapidFit divestment** [delivered]: Transfer to management team completed April 30, 2026.
- **Eyewear divestment** [delivered]: Sale closed July 1, 2026; Materialise retains 20% minority stake.
- **Lufthansa Technik partnership** [delivered]: Named official workbench for Lufthansa Technik metal parts after successful certified additive manufacturing project for aircraft cabin component.
- **Strike IP research consortium** [new]: Selected by Belgian Cyber Force and Royal Higher Institute for Defense to lead consortium with Sirus and Innocom for secure digital manufacturing of spare parts using Identify3D and CO-AM technology.
- **Investment in Replasia** [new]: Invested in Belgian medtech startup developing personalized 3D printing solutions for hip preservation, complementing existing hip replacement portfolio.

### Fears / risks

- **Macroeconomic environment**: Challenging macroeconomic environment persists, affecting industrial software spending and prototyping demand.
- **Software demand weakness**: Cautious customer spending and extended sales cycles in industrial environment; Software revenue declined 3% in Q2.
- **Medical software reimbursement risk**: US orthopedic reimbursement changes causing cautiousness from customers; academic research grant reductions impacting US academic segment software sales.
- **Prototyping demand weakness**: Continued weakness in prototyping demand offsetting Manufacturing series manufacturing growth.
- **Seasonality uncertainty**: Q3 typically softer, Q4 stronger; management hopes for typical seasonality but acknowledges uncertainty.
- **CO-AM adoption execution risk**: Growth dependent on successful adoption of CO-AM NPI and Enterprise offerings; early stages of early adopter programs.
- **Leadership transition in Medical**: Search for new Medical segment leader after Koen Peters departure; execution risk during transition.
- **Currency fluctuation impact**: Impact from currency fluctuations remained limited in Q2 but could affect future results.

### Key quotes

> “Our solid first half year performance reinforces our confidence in delivering on our financial targets.”

> “We believe that is also largely driven by the fact that we have been able to reduce our cost structure. You have to fill in that, that is also structural cost savings that we're doing there.”

> “The Pro offering is a step into the CO-AM offering as a first step which is a critical one because we want to get customers onto our cloud platform, but the major growth drivers will come from NPI and Enterprise.”

## Quarter one-liners

- **2026 Q2:** Materialise Q2 2026: Revenue up 8% to EUR 70.1M, Medical +12%, Software -3%, Manufacturing +7%; adjusted EBIT margin expands to 5.5%; net cash rises to EUR 74.2M; full-year revenue guidance maintained EUR 273-283M, adjusted EBIT guidance raised to EUR 12-14M; RapidFit and Eyewear divestments complet
- **2026 Q1:** Materialise Q1 2026: Revenue stable at EUR 66.3M despite FX headwinds; gross margin 57.2%, adj. EBIT EUR 2.5M (3.7%); Medical +7% (+10% cc), Software -1% (+5% cc), Manufacturing -8% but sequential growth in aerospace/defense/semicon. Divested RapidFit and Eyewear. Guidance maintained: revenue EUR 27
- **2025 Q4:** —
- **2025 Q3:** Materialise posted modest revenue growth but a 3.5% YoY decline, driven by strong double‑digit medical growth while software and manufacturing faced macro‑headwinds; FY2025 guidance was maintained.
- **2025 Q2:** —
- **2025 Q1:** —
- **2024 Q4:** Materialise posted 4% revenue growth and stable EBIT despite a tough macro environment, but warned of continued European industrial headwinds, higher costs from FEops integration and a new ACTech plant, while pushing cost control and subscription transition in 2025.
- **2024 Q3:** MTLS Q3 revenue €68.7M (+14% YoY), all segments grow; Medical now 44% of revenue, EBIT margin 6.4%; US plant triples trauma cases, Mimics Flow gains 10 customers, ACTech plant 2 opens Q4.

## Theme arcs

- **Medical revenue growth** (improving): From 44% of revenue and +14% YoY in Q3 2024 to sustained double‑digit growth and higher margin in 2026 despite FX pressure.
- **Software subscription transition** (improving): Shift from perpetual licenses to recurring revenue; recurring EBITDA up 88% YoY in Q1 2026, though sales cycles lengthen.
- **Manufacturing profitability** (deteriorating): Negative adjusted EBITDA in 2025 due to European headwinds and ACTech start‑up; turned positive by Q1 2026 as aerospace/defense demand recovered.
- **Macro‑economic headwinds** (deteriorating): High interest rates, geopolitical tension and soft European automotive demand cited repeatedly.
- **ACTech plant ramp‑up** (resolved): Initial capacity drag in Q4 2024 and 2025, no further mention after 2025 indicating resolution.
- **Foreign‑exchange impact** (new): FX headwinds affecting Medical and Software revenue noted from Q1 2026 onward.
- **Divestment focus** (new): RapidFit and Eyewear divestitures completed in 2026 to concentrate on core segments.
- **CO‑AM product suite** (new): CO‑AM Professional early access (2026 Q1) and full launch (2026 Q2) expand low‑code offering.
- **Cost discipline and margin expansion** (improving): Adjusted EBIT margin rose from 3.7% (Q1 2026) to 5.5% (Q2 2026) with stable gross margins.
- **Partnership strategy** (stable): Ongoing partnerships (Formlabs, Stratasys, Lufthansa Technik) remain a core growth lever.

## Fear persistence

- **Manufacturing market conditions** [recurring]: Repeatedly cited as challenging in 2024‑2025, with profitability pressure easing by 2026.
- **Software revenue transition** [recurring]: Long‑tail perpetual license tail noted in 2024, still a concern in 2026 despite recurring growth.
- **Macro‑economic headwinds** [recurring]: High interest rates, geopolitical tension, and soft European demand mentioned throughout.
- **European automotive weakness** [recurring]: Consistently flagged as a drag on manufacturing demand.
- **Integration costs (FEops)** [recurring]: Integration cost pressure noted in 2024 Q4 and continued relevance in 2025 milestones.

## Guidance path

2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:maintained → 2025 Q4:vague → 2026 Q1:maintained → 2026 Q2:raised

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/MTLS`